Working... Menu
Trial record 28 of 81 for:    CRVO - Central Retinal Vein Occlusion

Treatment of Bevacizumab and Triamcinolone in Treatment or Macular Edema Secondary to CRVO (MECROV)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00566761
Recruitment Status : Unknown
Verified November 2007 by Asociación para Evitar la Ceguera en México.
Recruitment status was:  Recruiting
First Posted : December 4, 2007
Last Update Posted : December 4, 2007
Information provided by:
Asociación para Evitar la Ceguera en México

Brief Summary:
Treatment of macular edema secondary to central retinal vein occlusion is more effective with combined therapy of bevacizumab and triamcinolone than bevacizumab alone.

Condition or disease Intervention/treatment Phase
Macular Edema Central Retinal Vein Occlusion Drug: bevacizumab and triamcinolone Phase 4

Detailed Description:
Comparison of two groups with different treatment with registrations of outcome in BCVA and complications

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Combined Treatment of Intravitreous Bevacizumab and Triamcinolone for the Treatment or Macular Edema Secondary to Central Retinal Vein Occlusion
Study Start Date : June 2007
Estimated Study Completion Date : March 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Edema

Intervention Details:
  • Drug: bevacizumab and triamcinolone
    three applications monthly administrated of bevacizumab 2.5mg for group 1 and bevacizumab 2.5 mg + triamcinolone 4mg first dose followed by two of bevacizumab alone for the group 2

Primary Outcome Measures :
  1. Changes in Best corrected visual acuity and macular edema measured with OCT [ Time Frame: Follow up to 3 , 6 and 12 months ]

Secondary Outcome Measures :
  1. Report treatment complications [ Time Frame: 12 month ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Macular edema secondary to central retinal vein occlusion
  • BCVA worse than 20/40
  • Central macular >250 mc with OCT

Exclusion Criteria:

  • Diabetic retinopathy or other retinopathy
  • Media opacity that does not allow following
  • steroid responder
  • diagnosed glaucoma or IOP > 21 mmHg

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00566761

Layout table for location contacts
Contact: Carmen Conzalez-Mijares, Physician 5517638245

Layout table for location information
Asociacion Para Evitar la Ceguera en Mexico Recruiting
Mexico city, Coyoacan, Mexico, 04030
Contact: Retina Department    5510841400 ext 1171   
Sponsors and Collaborators
Asociación para Evitar la Ceguera en México
Layout table for investigator information
Principal Investigator: Carmen Gonzalez-Mijares, Physician APEC
Study Director: Hugo Quiroz-Mercado, Retinologyst APEC
Study Chair: Juan Manuel Jimenez Sierra, Retinologyst APEC
Study Chair: MA Martinez-Castellanos, Physician APEC
Study Chair: Octavio Burgos Vejar, Physician APEC
Study Chair: Raul Velez-Montoya, Physician APEC
Study Chair: Ma de Lourdes Lopez Ramos, Physician APEC
Study Chair: Omar Honerlager, preresident APEC

Layout table for additonal information
Responsible Party: Carmen Cecilia Gonzalez Mijares, Asociación para Evitar la Ceguera en Mexico IAP Identifier: NCT00566761     History of Changes
Other Study ID Numbers: MECRVO
First Posted: December 4, 2007    Key Record Dates
Last Update Posted: December 4, 2007
Last Verified: November 2007

Keywords provided by Asociación para Evitar la Ceguera en México:
Macular edema
central retinal vein occlusion

Additional relevant MeSH terms:
Layout table for MeSH terms
Retinal Vein Occlusion
Retinal Degeneration
Retinal Diseases
Venous Thrombosis
Macular Edema
Signs and Symptoms
Macular Degeneration
Eye Diseases
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Triamcinolone Acetonide
Triamcinolone hexacetonide
Triamcinolone diacetate
Antineoplastic Agents, Immunological
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Anti-Inflammatory Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Immunosuppressive Agents